We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02354261
Recruitment Status : Completed
First Posted : February 3, 2015
Last Update Posted : August 5, 2020
Information provided by (Responsible Party):
HedgePath Pharmaceuticals, Inc.

Brief Summary:
The study will assess the safety and efficacy of SUBA-Cap in subjects with Basal Cell Carcinoma Nevus Syndrome.

Condition or disease Intervention/treatment Phase
Basal Cell Carcinoma in Basal Cell Nevus Syndrome Drug: SUBA-Itraconazole Phase 2

Detailed Description:

Single arm, phase IIb, multi-center, open-label study evaluating the use of oral SUBA-Cap in subjects with Basal Cell Carcinoma Nevus Syndrome and non-metastatic Basal Cell Carcinoma.

Following informed consent, subjects will undergo a skin biopsy for Gli1 analysis and an assessment of extent of disease using both tumor measurements (using modified Response Evaluation Criteria in Solid Tumors criteria) and color photographs of the skin.

Subjects will receive daily oral SUBA-Cap, at a starting dose of 150 mg twice daily (BID). Reassessments of disease will be conducted at weeks 4, 8, 16, and then every 8 weeks thereafter. Subjects with evidence of response (partial or complete) will be re-evaluated at least 4 weeks later for confirmation. Subjects may continue to receive SUBA-Cap until disease progression (defined as the appearance of one or more new lesions or ulceration of a target lesion) that requires a change in therapy (surgical intervention or use of other systemic therapy) or the appearance of unacceptable side effects. Pharmacokinetic assessments (serial trough levels) will be performed at defined intervals and, when possible, prior to and following any dose adjustment. Skin biopsies will be taken for Gli1 expression at defined intervals.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 38 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase IIb Open-label Trial of SUBA™-Itraconazole in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)
Actual Study Start Date : August 7, 2015
Actual Primary Completion Date : March 2019
Actual Study Completion Date : March 2019

Arm Intervention/treatment
Experimental: SUBA-Itraconazole
Subjects will receive an oral dose of 300 mg SUBA-itraconazole daily.
Drug: SUBA-Itraconazole
Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily.
Other Name: SUBA-Cap

Primary Outcome Measures :
  1. Response rate of BCC lesions [ Time Frame: Up to 26 weeks ]

Secondary Outcome Measures :
  1. Safety and tolerance; measured by number of subjects with adverse events [ Time Frame: Participants will be followed for the duration of study participation, an expected average of 26 weeks ]
  2. Number of new BCCs eligible for surgical resection [ Time Frame: Up to 26 weeks ]
  3. Duration of response in those subjects that have responded [ Time Frame: Up to 26 weeks ]
  4. Time to next therapy (systemic therapy or surgical intervention) [ Time Frame: Up to 26 weeks ]
  5. Change in the number of jaw cysts [ Time Frame: Up to 26 weeks ]
  6. Changes in the number of palmar/plantar pits [ Time Frame: Up to 26 weeks ]
  7. Gli1 expression in normal skin [ Time Frame: Up to 26 weeks ]
  8. Levels of itraconazole and hydroxy-itraconazole in the skin [ Time Frame: Up to 26 weeks ]
  9. Levels of itraconazole and hydroxy-itraconazole in the blood [ Time Frame: For Cycle 1 and Cycle 2, Up to week 8 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ECOG performance status of 0 or 1
  • Diagnosis of Basal Cell Carcinoma Nevus Syndrome (BCCNS)
  • Histologic confirmation of BCC from at least one lesion
  • History of surgical removal of at least ten (10) prior BCCs
  • Measurable disease as defined, namely at least ten (10) measurable lesions such that the sum of the longest diameters of the measurable lesions is at least 40 mm.
  • Has failed, refused, or is not eligible for standard of care therapy for BCC
  • Willingness to abstain from the use of non-study treatments for BCC, including but not limited to topical medications, PDT, and/or irradiation therapy.
  • At least four weeks from prior major surgery
  • Women who are pre-menopausal or not surgically sterile must be willing to use an acceptable contraceptive method for the duration of the study and for 30 days following the last dose of study drug
  • Sexually active men must be willing to use an acceptable contraceptive method for the duration of time on study and for 30 days following the last dose of study drug
  • Clinical laboratory values within the following ranges:

    1. Negative serum pregnancy test
    2. Adequate hematologic function (ANC ≥1.5 x 10^9/L; platelet count ≥75x10^9/L; hemoglobin ≥9g/dL (in the absence of red blood cell transfusions in the prior 14 days)
    3. Prothrombin time (PT-INR) or activated partial thromboplastin time (APTT) <1.5 times the upper limit of normal range, unless currently receiving anticoagulants
    4. Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥60 mL/min
    5. Total bilirubin ≤ 1.5x the upper limit of normal unless considered due to Gilbert syndrome in which case, ≤ 3x the upper limit of normal
    6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels ≤ the upper limit of normal
  • Willingness to undergo biopsies (BCC lesions and normal skin)
  • Willingness to provide prior and study-related BCC biopsies for central review
  • Willingness to participate in collection of pharmacokinetic samples
  • Willingness to not donate blood, semen, or eggs for the duration of the study and for 3 months following discontinuation of SUBA-Cap
  • Willingness to delay removal of otherwise surgically eligible BCC's

Exclusion Criteria:

  • Presence of metastatic BCC
  • Subjects who would be disserved significantly by a delay in conventional therapy, such as surgical intervention of their BCC
  • Prior use of a hedgehog inhibitor (e.g., sonidegib, vismodegib) or Itraconazole within the past 6 months
  • History of progressive disease on a hedgehog inhibitor (e.g., sonidegib, vismodegib) or other Hh pathway inhibitors for the treatment of BCC
  • Pregnant and/or nursing women
  • Use of any medications metabolized by the cytochrome P450 3A4 isoenzyme system (CYP3A4) known to lead to potentially serious and/or life threatening adverse events when used in conjunction with itraconazole
  • Any illness that is likely to reduce absorption of oral medications
  • Corrected QT (Fridericia) interval of >450 msec for females and >430 msec for males
  • Use of any medications known to result in a prolongation of the QT interval
  • History of congestive heart failure or other cardiac abnormality that would contraindicate the use of itraconazole
  • Any condition or situation which in the Investigator's opinion may put the subject at significant risk, could confound the study results, or could interfere significantly with the subject's participation in the study
  • Any indication of compromised liver function that would otherwise contraindicate use of itraconazole
  • Any concurrent malignancy, except for squamous cell carcinoma of the skin and cervical carcinoma in situ, that is likely to require treatment within the next two years or would interfere with study requirements
  • Psychiatric illness and/or social situations (e.g., excessive alcohol use or use of illicit drugs) that would interfere with study compliance
  • Known HIV infection, active hepatitis B or active hepatitis C infection (testing not required unless indicated by history)
  • Known allergy to itraconazole or any of its excipients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02354261

Layout table for location information
United States, California
Dermatology Specialists, Inc
Oceanside, California, United States, 92056
United States, Florida
Ameriderm Research
Ormond Beach, Florida, United States, 32174
United States, Michigan
Grekin Skin Institute
Warren, Michigan, United States, 48034
United States, New York
Stony Brook University
East Setauket, New York, United States, 11733
United States, Pennsylvania
Penn State Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
Sponsors and Collaborators
HedgePath Pharmaceuticals, Inc.
Layout table for investigator information
Principal Investigator: James Solomon, MD, PhD Ameriderm Clinical Research
Layout table for additonal information
Responsible Party: HedgePath Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT02354261    
Other Study ID Numbers: HP2001
SCORING ( Other Identifier: HedgePath )
First Posted: February 3, 2015    Key Record Dates
Last Update Posted: August 5, 2020
Last Verified: August 2020
Keywords provided by HedgePath Pharmaceuticals, Inc.:
Basal Cell Carcinoma Nevus Syndrome
basal cell carcinoma
locally advanced basal cell carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Basal Cell
Basal Cell Nevus Syndrome
Pathologic Processes
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Basal Cell
Nevi and Melanomas
Odontogenic Cysts
Jaw Cysts
Bone Cysts
Neoplastic Syndromes, Hereditary
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Jaw Diseases
Stomatognathic Diseases
Abnormalities, Multiple
Congenital Abnormalities
Genetic Diseases, Inborn
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors